🟢 20/20 Biolabs is trading 6.4% up today as AMIA recognition of its clinical AI tools sustains momentum

20/20 Biolabs is trading at $0.61 (6.4% up) as the company continues to see positive momentum following industry recognition of its artificial intelligence technology.

• The stock is rebounding from a weak July 7 session, extending the upward trend that began during the July 8 pre-market.
• Investor interest appears sustained by the earlier recognition of the company's DARWEN-powered clinical AI tools by the American Medical Informatics Association (AMIA).